Free Trial

Aptamer Group (APTA) Competitors

Aptamer Group logo
GBX 0.36 -0.04 (-10.50%)
As of 11:41 AM Eastern

APTA vs. HVO, C4XD, DDDD, IXI, and COIL

Should you buy Aptamer Group stock or one of its competitors? Aptamer Group's main competitors and comparable companies include hVIVO (HVO), C4X Discovery (C4XD), 4D pharma (DDDD), IXICO (IXI), and Roquefort Therapeutics (COIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aptamer Group compare to hVIVO?

hVIVO (LON:HVO) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

hVIVO presently has a consensus price target of GBX 16.33, suggesting a potential upside of 222.16%. Given hVIVO's stronger consensus rating and higher possible upside, analysts clearly believe hVIVO is more favorable than Aptamer Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Aptamer Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

hVIVO has a net margin of -31.76% compared to Aptamer Group's net margin of -120.60%. hVIVO's return on equity of -35.13% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-31.76% -35.13% 11.97%
Aptamer Group -120.60%-46.61%-44.96%

hVIVO has a beta of 1.656, indicating that its share price is 66% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.871, indicating that its share price is 13% less volatile than the broader market.

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
hVIVO Neutral
Aptamer Group Neutral

12.7% of hVIVO shares are held by institutional investors. Comparatively, 4.3% of Aptamer Group shares are held by institutional investors. 4.9% of hVIVO shares are held by company insiders. Comparatively, 7.6% of Aptamer Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

hVIVO has higher revenue and earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£38.85M0.90£17.84M-£1.78N/A
Aptamer Group£1.54M8.04-£14.17M-£0.07N/A

Summary

hVIVO beats Aptamer Group on 11 of the 14 factors compared between the two stocks.

How does Aptamer Group compare to C4X Discovery?

Aptamer Group (LON:APTA) and C4X Discovery (LON:C4XD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Aptamer Group has a beta of 0.871, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, C4X Discovery has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

4.3% of Aptamer Group shares are held by institutional investors. Comparatively, 52.1% of C4X Discovery shares are held by institutional investors. 7.6% of Aptamer Group shares are held by company insiders. Comparatively, 27.1% of C4X Discovery shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

C4X Discovery has higher revenue and earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptamer Group£1.54M8.04-£14.17M-£0.07N/A
C4X Discovery£24.68M0.00£10.57M£0.04N/A

C4X Discovery has a net margin of 42.81% compared to Aptamer Group's net margin of -120.60%. C4X Discovery's return on equity of 55.38% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptamer Group-120.60% -46.61% -44.96%
C4X Discovery 42.81%55.38%28.04%

In the previous week, C4X Discovery's average media sentiment score of 0.68 beat Aptamer Group's score of 0.00 indicating that C4X Discovery is being referred to more favorably in the news media.

Company Overall Sentiment
Aptamer Group Neutral
C4X Discovery Positive

Summary

C4X Discovery beats Aptamer Group on 10 of the 11 factors compared between the two stocks.

How does Aptamer Group compare to 4D pharma?

4D pharma (LON:DDDD) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Aptamer Group has higher revenue and earnings than 4D pharma. Aptamer Group is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D pharma£718K0.00-£31.94M-£15.40N/A
Aptamer Group£1.54M8.04-£14.17M-£0.07N/A

4D pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -120.60%. Aptamer Group's return on equity of -46.61% beat 4D pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
4D pharmaN/A -89.48% -42.64%
Aptamer Group -120.60%-46.61%-44.96%

In the previous week, 4D pharma's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
4D pharma Neutral
Aptamer Group Neutral

4D pharma has a beta of 2.63, indicating that its share price is 163% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.871, indicating that its share price is 13% less volatile than the broader market.

26.8% of 4D pharma shares are held by institutional investors. Comparatively, 4.3% of Aptamer Group shares are held by institutional investors. 12.2% of 4D pharma shares are held by insiders. Comparatively, 7.6% of Aptamer Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

4D pharma beats Aptamer Group on 6 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to IXICO?

Aptamer Group (LON:APTA) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled IXICO'saverage media sentiment score.

Company Overall Sentiment
Aptamer Group Neutral
IXICO Neutral

4.3% of Aptamer Group shares are owned by institutional investors. Comparatively, 23.5% of IXICO shares are owned by institutional investors. 7.6% of Aptamer Group shares are owned by insiders. Comparatively, 3.1% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IXICO has higher revenue and earnings than Aptamer Group. IXICO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptamer Group£1.54M8.04-£14.17M-£0.07N/A
IXICO£7.28M3.91-£3.58M-£1.95N/A

Aptamer Group has a beta of 0.871, indicating that its stock price is 13% less volatile than the broader market. Comparatively, IXICO has a beta of 0.106, indicating that its stock price is 89% less volatile than the broader market.

IXICO has a net margin of -24.98% compared to Aptamer Group's net margin of -120.60%. IXICO's return on equity of -16.18% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptamer Group-120.60% -46.61% -44.96%
IXICO -24.98%-16.18%-10.40%

Summary

IXICO beats Aptamer Group on 6 of the 11 factors compared between the two stocks.

How does Aptamer Group compare to Roquefort Therapeutics?

Aptamer Group (LON:APTA) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Aptamer Group has a beta of 0.871, indicating that its share price is 13% less volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market.

In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Aptamer Group Neutral
Roquefort Therapeutics Neutral

Aptamer Group has a net margin of -120.60% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptamer Group-120.60% -46.61% -44.96%
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

Roquefort Therapeutics has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptamer Group£1.54M8.04-£14.17M-£0.07N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£20.24N/A

4.3% of Aptamer Group shares are held by institutional investors. Comparatively, 1.8% of Roquefort Therapeutics shares are held by institutional investors. 7.6% of Aptamer Group shares are held by company insiders. Comparatively, 36.3% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Aptamer Group and Roquefort Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Aptamer Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APTA vs. The Competition

MetricAptamer GroupBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£12.42M£4.09B£7.86B£2.84B
Dividend YieldN/A3.64%2.47%5.11%
P/E Ratio-5.1124.3834.4123.37
Price / Sales8.0415.078.095.05
Price / CashN/A21.8921.0220.23
Price / Book1.684.374.782.51
Net Income-£14.17M-£24.19M£3.52B£5.88B
7 Day Performance28.78%-6.84%-4.98%-0.01%
1 Month Performance11.88%-4.52%-3.20%-2.14%
1 Year Performance-65.90%-4.21%-0.27%7.21%

Aptamer Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APTA
Aptamer Group
N/AGBX 0.36
-10.5%
N/A-61.9%£12.42M£1.54MN/A30
HVO
hVIVO
N/AGBX 5
-2.0%
GBX 16.33
+226.7%
-21.9%£34.42M£38.85MN/AN/A
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049
DDDD
4D pharma
N/AN/AN/AN/A£30.05M£718KN/A106
IXI
IXICO
N/AGBX 13.17
+1.3%
N/A+15.7%£28.85M£7.28MN/A79

Related Companies and Tools


This page (LON:APTA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners